Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...
A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled “Bridging clinical insight and ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
News-Medical.Net on MSN
Study validates OVCAR3 as a model for high-grade serous ovarian cancer
A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...
Detailed price information for Os Therapies Incorporated (OSTX-A) from The Globe and Mail including charting and trades.
TAMPA, Fla. — Every year, the state’s Department of Education releases grades for school districts across the state based on a number of things, but primarily, on test scores, and the Hillsborough ...
HHS’s Health Resources and Services Administration released updated guidance for cervical cancer screening, which includes a ...
Heart disease has long been the top killer of women in the United States, but new research suggests uterine fibroids, which many may not even be aware they have, could be putting them at a ...
SurvivorNet on MSN
Enhertu significantly cuts recurrence rates for women with high-risk HER2-positive breast cancer — the practice-changing DESTINY-Breast05 trial
DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback